Demonstrates increased bone mineral density and bone formation with romosozumab in postmenopausal women, indicating potential to counteract bone loss.
In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
No takes yet. Share an insight, caveat, or question.
McClung et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: